Paola M Brown
The COVID-19 pandemic has necessitated the development of breast cancer treatment prioritisation policies, with patients with advanced disease, such as triple-negative breast cancer (TNBC), receiving top priority for clinical intervention. We summarise how COVID-19 has affected TNBC management so far and highlight areas where more data is required to fine-tune changing guidelines. TNBC management during the pandemic poses problems beyond the limits of overburdened healthcare systems, due to the immunocompromised state of most TNBC patients seeking treatment. During the COVID-19 outbreak, we performed a literature review of clinical recommendations for both primary and targeted TNBC therapeutic methods, noting improvements in treatment timing and drugs of choice.
